3 Stocks Boosting The Health Care Sector Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 91 points (0.6%) at 16,492 as of Wednesday, May 7, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,744 issues advancing vs. 1,239 declining with 163 unchanged.

The Health Care sector currently sits down 1.4% versus the S&P 500, which is up 0.3%. Top gainers within the sector include Herbalife ( HLF), up 4.3%, AbbVie ( ABBV), up 2.9%, UnitedHealth Group ( UNH), up 1.8%, WellPoint ( WLP), up 1.7% and Aetna ( AET), up 1.6%. On the negative front, top decliners within the sector include Perrigo ( PRGO), down 8.4%, Incyte ( INCY), down 3.2%, Vertex Pharmaceuticals ( VRTX), down 2.5%, Actavis ( ACT), down 1.6% and Bristol-Myers Squibb Company ( BMY), down 1.4%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Care sector higher today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is up $0.47 (1.4%) to $33.83 on average volume. Thus far, 74,516 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 146,000 shares. The stock has ranged in price between $33.53-$33.86 after having opened the day at $33.67 as compared to the previous trading day's close of $33.36.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides renal dialysis products and services. Fresenius Medical Care AG & Co. KGaA has a market cap of $20.7 billion and is part of the health services industry. Shares are down 6.2% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst who rates Fresenius Medical Care AG & Co. KGaA a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Humana ( HUM) is up $4.47 (4.1%) to $114.26 on heavy volume. Thus far, 2.0 million shares of Humana exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $107.99-$114.44 after having opened the day at $110.02 as compared to the previous trading day's close of $109.79.

Humana Inc., a health care company, offers a range of insurance products, and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in Retail, Employer Group, Healthcare Services, and Other Businesses segments. Humana has a market cap of $17.0 billion and is part of the health services industry. Shares are up 6.4% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts who rate Humana a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Humana Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Cigna ( CI) is up $0.87 (1.0%) to $84.74 on average volume. Thus far, 986,626 shares of Cigna exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $83.79-$84.87 after having opened the day at $84.00 as compared to the previous trading day's close of $83.87.

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. Cigna has a market cap of $22.5 billion and is part of the health services industry. Shares are down 4.1% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Cigna a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, revenue growth and impressive record of earnings per share growth. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Cigna Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Mining and Resources Lead Europe's Benchmarks Lower

Mining and Resources Lead Europe's Benchmarks Lower

European Stocks Diverge as Investors Weigh Economic Optimism With Mixed Earnings

European Stocks Diverge as Investors Weigh Economic Optimism With Mixed Earnings

Wednesday's Earnings Push Stocks Lower as Mood Sours in Europe

Wednesday's Earnings Push Stocks Lower as Mood Sours in Europe

Here's What's Boosting European Benchmarks

Here's What's Boosting European Benchmarks

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space